Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare Biotechnology

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by Stylesson Aug 23, 2015 5:03pm

26 Views

Post# 24044089

RE:RE:RE:RE:Idiot

right. excuses excuses.

I sold my shares of CPH at 9.75 after a double. I then bought PHM, CRH, and NHC where i averaged a return of ~8-10x.

I really lost out not holding to this dud.haha You're so right Lieseeker. SO right

It was clear this was a sell when market share growth decelerated and the lawsuit came up. Then they did the worse M&A deal they could have done. The days of 15+ share price are behind them.

You can blame the partners, but the company has not used its cash effectively. All the momentum guys are long gone now and dumbo retail like you are holding the bag.

Bullboard Posts

Global Tungsten Market and Supply Security